Grace Therapeutics, Inc. (GRCE) Stock Forecast & Price Target
Grace Therapeutics, Inc. · NASDAQ
$2.29-0.04 (-1.72%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Grace Therapeutics, Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $8.00 to $8.00, so the covering firms are broadly aligned. The average target of $8.00 sits 249% above the current $2.29. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.18 next quarter toward $-0.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Moderate Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Grace Therapeutics, Inc.
As of Jul, 1 of 1 firms rate GRCE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GRCE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.18 – $-0.18 · 1 analysts · +119% YoY
Next period, 1 analysts expect Grace Therapeutics, Inc. to earn $-0.18 a share (range $-0.18 – $-0.18), versus $-0.08 a year earlier. Full-year consensus is $-0.74, growing to $-0.77 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $7.8M next year.
Top analysts covering Grace Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GRCE.
#1
Oren Livnat
HC Wainwright & Co. · Rank #142
Buy
$12.00+424.0% to target
Overall win rate
54%
+ Follow
#2
SK
Stacy Ku
TD Cowen
Buy
$8.00+249.3% to target
Coverage
—
+ Follow
GRCE stock forecast FAQ
What is GRCE's average 12-month price target?+
The 1 analysts with a live target average $8.00 for Grace Therapeutics, Inc. over the next 12 months, ranging from a $8.00 high to a $8.00 low.
Is GRCE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover GRCE?+
1 analysts have an active rating on Grace Therapeutics, Inc., and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering GRCE?+
Among analysts who currently cover GRCE, Oren Livnat of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #142). Their current call is Buy with a $12.00 target.
What is Grace Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.18 – $-0.18) across 1 analysts. Full-year EPS is projected at $-0.74, rising to $-0.77 the following year.
How much revenue is Grace Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $7.8M next year.
Have analysts been upgrading or downgrading GRCE lately?+
As of Jul, 1 of 1 firms rate GRCE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GRCE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
